Browsing: PPD

Large molecule quantification by LC–MS PPD IMage
0

Monoclonal antibody (mAb) based biotherapeutics have emerged as a dominant class of approved medicines during the past decade in both market share and variety of target diseases. Ligand binding assays (LBAs), such as enzyme-linked immunosorbent assays (ELISA), have been the gold standard for the bioanalysis of mAbs in support of non-clinical and clinical trials. While conventional LBAs provide highly sensitive and specific detection for the quantitation of mAbs, combining an LBA with liquid chromatography tandem mass spectrometry (LC-MS/MS) detection offers additional orthogonal dimensions of selectivity/specificity, extending the assay utility to a multiplexed format otherwise not achievable by LBA alone.

Ask the Experts ATE HRMS (1)_Feature
0

To address questions raised in our Quantitative HRMS Spotlight and to investigate how the field has progressed over the last two years, key figures from pharma, CROs, biotech and academia share with us their experiences and thoughts on HRMS, giving our members a 360° opinion piece. Find out what Diego Cortes (PPD) thinks in this interview.